Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Jay Cohn

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Hemodynamics

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
21
Anand, Inder
17
Latini, Roberto
14
McDonald, KM
14
Tognoni, Gianni
14
Ziesche, Susan
13
Finkelstein, Stanley
12
Glazer, Robert
12
Worcel, Manuel
11
Masson, Serge
11
Taylor, Anne
11
Maggioni, Aldo
11
Barlera, Simona
10
Sabolinski, Michael
9
Tam, William
9
McVeigh, GE

Sign-in to see all Coauthors

Publications

TOP 3
Cohn Jay N
The president's page: target response or target dose.
Cohn Jay N
Conflicts of interest: to eliminate them or manage them.
McNamara Dennis M; Tam S William; Sabolinski Michael L; Tobelmann Page; Janosko Karen; Venkitachalam Lakshmi; Ofili Elizabeth; Yancy Clyde; Feldman Arthur M; Ghali Jalal K; Taylor Anne L; Cohn Jay N; Worcel Manuel
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jay Cohn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Cohn Jay N
The president's page: target response or target dose.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2009;23(4):337.
2009: Cohn Jay N
Conflicts of interest: to eliminate them or manage them.
Journal of cardiac failure 2009;15(5):375-6.
2009: McNamara Dennis M; Tam S William; Sabolinski Michael L; Tobelmann Page; Janosko Karen; Venkitachalam Lakshmi; Ofili Elizabeth; Yancy Clyde; Feldman Arthur M; Ghali Jalal K; Taylor Anne L; Cohn Jay N; Worcel Manuel
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.
Journal of cardiac failure 2009;15(3):191-8.
2009: Cohn Jay N; Wilson Daniel J; Neutel Joel; Houston Mark; Weinberger Myron H; Grimm Richard; Smith David H G; Sun William
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
American journal of hypertension 2009;22(2):137-44.
2008: Ghali Jalal K; Tam S William; Sabolinski Michael L; Taylor Anne L; Lindenfeld Joann; Cohn Jay N; Worcel Manuel
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Journal of cardiac failure 2008;14(9):718-23.
2008: Cohn Jay N
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Nature clinical practice. Cardiovascular medicine 2008;5(9):526-7.
2008: Cohn Jay N; Duprez Daniel A
Time to foster a rational approach to preventing cardiovascular morbid events.
Journal of the American College of Cardiology 2008;52(5):327-9.
2008: Anand Inder S; Rector Thomas S; Kuskowski Michael; Thomas Sabu; Holwerda N J; Cohn Jay N
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Circulation. Heart failure 2008;1(1):34-42.
2008: Duprez Daniel A; Cohn Jay N
Identifying early cardiovascular disease to target candidates for treatment.
Journal of clinical hypertension (Greenwich, Conn.) 2008;10(3):226-31.
2008: Cohn Jay N; Goldman Jesse M
Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
American journal of hypertension 2008;21(3):248-56.
2007: Staszewsky Lidia; Wong Maylene; Masson Serge; Barlera Simona; Carretta Elisa; Maggioni Aldo P; Anand Inder S; Cohn Jay N; Tognoni Gianni; Latini Roberto;
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Journal of cardiac failure 2007;13(10):797-804.
2007: Latini Roberto; Masson Serge; Anand Inder S; Missov Emil; Carlson Marjorie; Vago Tarcisio; Angelici Laura; Barlera Simona; Parrinello Giovanni; Maggioni Aldo P; Tognoni Gianni; Cohn Jay N;
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.
Circulation 2007;116(11):1242-9.
2007: Cohn Jay N; Tam S William; Anand Inder S; Taylor Anne L; Sabolinski Michael L; Worcel Manuel;
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
Journal of cardiac failure 2007;13(5):331-9.
2007: Taylor Anne L; Ziesche Susan; Yancy Clyde W; Carson Peter; Ferdinand Keith; Taylor Malcolm; Adams Kirkwood; Olukotun Adeoye Y; Ofili Elizabeth; Tam S William; Sabolinski Michael L; Worcel Manuel; Cohn Jay N;
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
Circulation 2007;115(13):1747-53.
2007: Cicoira Mariantonietta; Maggioni Aldo Pietro; Latini Roberto; Barlera Simona; Carretta Elisa; Janosi Andras; Soler Soler Jordi; Anand Inder; Cohn Jay N;
Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2007;9(4):397-402.
2007: Anand Inder S; Tam S William; Rector Thomas S; Taylor Anne L; Sabolinski Michael L; Archambault W Tad; Adams Kirkwood F; Olukotun Adeoye Y; Worcel Manuel; Cohn Jay N
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.
Journal of the American College of Cardiology 2007;49(1):32-9.
2007: Ghali Jalal K; Tam S William; Ferdinand Keith C; Lindenfeld JoAnn; Sabolinski Michael L; Taylor Anne L; Worcel Manuel; Curry Charles L; Cohn Jay N;
Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2007;7(5):373-80.
2007: Tam S William; Sabolinski Michael L; Worcel Manuel; Packer Milton; Cohn Jay N
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Clinical pharmacokinetics 2007;46(10):885-95.
2006: Taylor Anne L; Lindenfeld JoAnn; Ziesche Susan; Walsh Mary Norine; Mitchell Judith E; Adams Kirkwood; Tam S William; Ofili Elizabeth; Sabolinski Michael L; Worcel Manuel; Cohn Jay N;
Outcomes by gender in the African-American Heart Failure Trial.
Journal of the American College of Cardiology 2006;48(11):2263-7.
2006: Cohn Jay N
What is the role of angiotensin-receptor blockade in cardiovascular protection?
American heart journal 2006;152(5):859.e1-8.
2006: McNamara Dennis M; Tam S William; Sabolinski Michael L; Tobelmann Page; Janosko Karen; Taylor Anne L; Cohn Jay N; Feldman Arthur M; Worcel Manuel
Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial.
Journal of the American College of Cardiology 2006;48(6):1277-82.
2006: Cohn Jay N
Efficacy and safety in clinical trials in cardiovascular disease.
Journal of the American College of Cardiology 2006;48(3):430-3.
2006: Masson Serge; Latini Roberto; Anand Inder S; Vago Tarcisio; Angelici Laura; Barlera Simona; Missov Emil D; Clerico Aldo; Tognoni Gianni; Cohn Jay N;
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
Clinical chemistry 2006;52(8):1528-38.
2006: Wong Maylene; Staszewsky Lidia; Carretta Elisa; Barlera Simona; Latini Roberto; Chiang Yann-Tong; Glazer Robert D; Cohn Jay N
Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2006;8(5):502-8.
2006: Masson Serge; Latini Roberto; Anand Inder S; Barlera Simona; Judd Dianne; Salio Monica; Perticone Francesco; Perini Giampaolo; Tognoni Gianni; Cohn Jay N;
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT).
Journal of cardiac failure 2006;12(5):375-80.
2006: Cohn Jay N; Carson Peter E; O'Connor Christopher; Opasich Cristina; Piña Ileana L; Scherillo Marino; Sinagra Gianfranco; Warner-Stevenson Lynne; Tristani Felix E; Volpi Alberto
Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.
Congestive heart failure (Greenwich, Conn.) 2006;12(3):127-31.
2006: Cohn Jay N; Colucci Wilson
Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.
The American journal of cardiology 2006;97(10A):4F-12F.
2006: Rector Thomas S; Anand Inder S; Cohn Jay N
Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life.
Journal of cardiac failure 2006;12(2):87-92.
2006: Latini Roberto; Masson Serge; Wong Maylene; Barlera Simona; Carretta Elisa; Staszewsky Lidia; Vago Tarciso; Maggioni Aldo P; Anand Inder S; Tan Lip B; Tognoni Gianni; Cohn Jay N;
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
The American journal of medicine 2006;119(1):70.e23-30.
2005: Anand Inder S; Latini Roberto; Florea Viorel G; Kuskowski Michael A; Rector Thomas; Masson Serge; Signorini Stefano; Mocarelli Paolo; Hester Allen; Glazer Robert; Cohn Jay N;
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Circulation 2005;112(10):1428-34.
2005: Anand Inder S; Kuskowski Michael A; Rector Thomas S; Florea Viorel G; Glazer Robert D; Hester Allen; Chiang Yann Tong; Aknay Nora; Maggioni Aldo P; Opasich Cristina; Latini Roberto; Cohn Jay N
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Circulation 2005;112(8):1121-7.
2005: Cohn Jay N; Duprez Daniel A; Grandits Gregory A
Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment.
Hypertension 2005;46(1):217-20.
2005: Majani Giuseppina; Giardini Anna; Opasich Cristina; Glazer Robert; Hester Allen; Tognoni Gianni; Cohn Jay N; Tavazzi Luigi
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
Journal of cardiac failure 2005;11(4):253-9.
2005: Maggioni Aldo P; Latini Roberto; Carson Peter E; Singh Steven N; Barlera Simona; Glazer Robert; Masson Serge; Cerè Elisabetta; Tognoni Gianni; Cohn Jay N;
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
American heart journal 2005;149(3):548-57.
2004: Cohn Jay N
New therapeutic strategies for heart failure: left ventricular remodeling as a target.
Journal of cardiac failure 2004;10(6 Suppl):S200-1.
2004: Baruch Lawrence; Glazer Robert D; Aknay Nora; Vanhaecke Johan; Heywood J Thomas; Anand Inder; Krum Henry; Hester Allen; Cohn Jay N
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
American heart journal 2004;148(6):951-7.
2004: Krum Henry; Carson Peter; Farsang Csaba; Maggioni Aldo P; Glazer Robert D; Aknay Nora; Chiang Yann-Tong; Cohn Jay N
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2004;6(7):937-45.
2004: Taylor Anne L; Ziesche Susan; Yancy Clyde; Carson Peter; D'Agostino Ralph; Ferdinand Keith; Taylor Malcolm; Adams Kirkwood; Sabolinski Michael; Worcel Manuel; Cohn Jay N;
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
The New England journal of medicine 2004;351(20):2049-57.
2004: Duprez Daniel A; Kaiser Daniel R; Whitwam Wayne; Finkelstein Stanley; Belalcazar Andres; Patterson Robert; Glasser Stephen; Cohn Jay N
Determinants of radial artery pulse wave analysis in asymptomatic individuals.
American journal of hypertension 2004;17(8):647-53.
2004: Cohn Jay N
Introduction to surrogate markers.
Circulation 2004;109(25 Suppl 1):IV20-1.
2004: Wong Maylene; Staszewsky Lidia; Latini Roberto; Barlera Simona; Glazer Robert; Aknay Nora; Hester Allen; Anand Inder; Cohn Jay N
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.
Journal of the American College of Cardiology 2004;43(11):2022-7.
2004: Cohn Jay N
The James B. Herrick Award Lecture. 2003. Clinical research: whose agenda is it?
Circulation 2004;109(19):2256-62.
2004: Latini Roberto; Masson Serge; Anand Inder; Salio Monica; Hester Allen; Judd Dianne; Barlera Simona; Maggioni Aldo P; Tognoni Gianni; Cohn Jay N;
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.
European heart journal 2004;25(4):292-9.
2004: Cohn Jay N; Julius Stevo; Neutel Joel; Weber Michael; Turlapaty Prasad; Shen Yannan; Dong Victor; Batchelor Alicia; Guo Weinong; Lagast Hjalmar
Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial.
American journal of hypertension 2004;17(2):134-8.
2004: Julius Stevo; Cohn Jay N; Neutel Joel; Weber Michael; Turlapaty Prasad; Shen Yannan; Dong Victor; Batchelor Alicia; Lagast Hjalmar
Antihypertensive utility of perindopril in a large, general practice-based clinical trial.
Journal of clinical hypertension (Greenwich, Conn.) 2004;6(1):10-7.
2004: Neutel Joel M; Weber Michael A; Julius Stevo; Cohn Jay N; Turlapaty Prasad; Shen Yannan; Guo Weinong; Batchelor Alicia; Lagast Hjalmar
Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2004;4(5):335-41.
2003: Cohn Jay N
Beta-blockers for heart failure.
Journal of cardiac failure 2003;9(6):458.
2003: Cohn Jay N; Loscalzo Joseph; Franciosa Joseph A
Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction.
Journal of cardiac failure 2003;9(5 Suppl Nitric Oxide):S197-8.
2003: Cohn Jay N
Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2003;4(3):137-9.
2003: Cohn Jay N; Anand Inder S; Latini Roberto; Masson Serge; Chiang Yann-Tong; Glazer Robert;
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Circulation 2003;108(11):1306-9.
2003: Grey Elizabeth; Bratteli Chris; Glasser Stephen P; Alinder Cheryl; Finkelstein Stanley M; Lindgren Bruce R; Cohn Jay N
Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events.
American journal of hypertension 2003;16(4):265-9.
2003: Anand Inder S; Fisher Lloyd D; Chiang Yann-Tong; Latini Roberto; Masson Serge; Maggioni Aldo P; Glazer Robert D; Tognoni Gianni; Cohn Jay N;
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
Circulation 2003;107(9):1278-83.
2002: Cohn Jay N
Global structural ventricular remodeling: summation.
Journal of cardiac failure 2002;8(6 Suppl):S269-70.
2002: Latini Roberto; Masson Serge; Anand Inder; Judd Dianne; Maggioni Aldo P; Chiang Yann-Tong; Bevilacqua Maurizio; Salio Monica; Cardano Paola; Dunselman Peter H J M; Holwerda Nicolaas J; Tognoni Gianni; Cohn Jay N;
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Circulation 2002;106(19):2454-8.
2002: Cohn Jay N
Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
The American journal of cardiology 2002;90(9):992-3.
2002: Maggioni Aldo P; Anand Inder; Gottlieb Sidney O; Latini Roberto; Tognoni Gianni; Cohn Jay N;
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Journal of the American College of Cardiology 2002;40(8):1414-21.
2002: Taylor Anne L; Cohn Jay N; Worcel Manuel; Franciosa Joseph A;
The African-American Heart Failure Trial: background, rationale and significance.
Journal of the National Medical Association 2002;94(9):762-9.
2002: Wong Maylene; Staszewsky Lidia; Latini Roberto; Barlera Simona; Volpi Alberto; Chiang Yann-Tong; Benza Raymond L; Gottlieb Sidney O; Kleemann Thomas D; Rosconi Franco; Vandervoort Pieter M; Cohn Jay N;
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
Journal of the American College of Cardiology 2002;40(5):970-5.
2002: Franciosa Joseph A; Taylor Anne L; Cohn Jay N; Yancy Clyde W; Ziesche Susan; Olukotun Adeoye; Ofili Elizabeth; Ferdinand Keith; Loscalzo Joseph; Worcel Manuel;
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
Journal of cardiac failure 2002;8(3):128-35.
2002: Leier Carl V; Silver Marc A; Rich Michael W; Eichhorn Eric J; Fowler Michael B; Giles Thomas D; Johnstone David E; Le Jemtel Thierry H; Lachmann Justine S; Levine T Barry; Armstrong Paul W; Dec William G; Jessup Mariell; Howlett Jonathan; Hershberger Raymond E; Cohn Jay N; Adams Kirkwood F; Colucci Wilson S; Warner-Stevenson Lynne; Hosenpud Jeffrey D; Bristow Michael R; Pina Ileana; Baughman Kenneth L; Binkley Philip F; Ventura Hector O; Francis Gary S; White Michel; Miller Leslie W; Berry Brandy; Missov Emil
Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment.
Congestive heart failure (Greenwich, Conn.) 2002;8(2):98-124.
2001: Cohn J N; Tognoni G;
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
The New England journal of medicine 2001;345(23):1667-75.
2001: Beltran A; McVeigh G; Morgan D; Glasser S P; Neutel J M; Weber M; Finkelstein S M; Cohn J N
Arterial compliance abnormalities in isolated systolic hypertension.
American journal of hypertension 2001;14(10):1007-11.
2001: Cohn J N
Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making.
American journal of hypertension 2001;14(8 Pt 2):258S-263S.
2001: Cohn J N
New approaches to screening for vascular and cardiac risk.
American journal of hypertension 2001;14(6 Pt 2):218S-220S.
2001: Fowler M B; Vera-Llonch M; Oster G; Bristow M R; Cohn J N; Colucci W S; Gilbert E M; Lukas M A; Lacey M J; Richner R; Young S T; Packer M
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
Journal of the American College of Cardiology 2001;37(6):1692-9.
2001: Yancy C W; Fowler M B; Colucci W S; Gilbert E M; Bristow M R; Cohn J N; Lukas M A; Young S T; Packer M;
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
The New England journal of medicine 2001;344(18):1358-65.
2001: Arnett D K; Glasser S P; McVeigh G; Prineas R; Finklestein S; Donahue R; Cohn J N; Sinaiko A
Blood pressure and arterial compliance in young adults: the Minnesota Children's Blood Pressure Study.
American journal of hypertension 2001;14(3):200-5.
2001: Cohn J N
Left ventricle and arteries: structure, function, hormones, and disease.
Hypertension 2001;37(2 Part 2):346-9.
2000: Cohn J N; Tognoni G; Glazer R; Spormann D
Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2000;2(4):439-46.
2000: Reis S E; Holubkov R; Young J B; White B G; Cohn J N; Feldman A M
Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies.
Journal of the American College of Cardiology 2000;36(2):529-33.
2000: Nicklas J M; Cohn J N; Pitt B
What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure?
Journal of cardiac failure 2000;6(2):165-8.
2000: Smith R F; Germanson T; Judd D; Wong M; Ziesche S; Anand I S; Taylor W R; Cohn J N
Plasma norepinephrine and atrial natriuretic peptide in heart failure: influence of felodipine in the third Vasodilator Heart Failure Trial. V-HeFT III investigators.
Journal of cardiac failure 2000;6(2):97-107.
2000: Wong M; Germanson T; Taylor W R; Cohen I S; Perry G; Baruch L; Deedwania P; Lopez B; Cohn J N
Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change.
Journal of cardiac failure 2000;6(1):19-28.
2000: Cohn J N; Ferrari R; Sharpe N
Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.
Journal of the American College of Cardiology 2000;35(3):569-82.
1999: Cohn J N
Vascular wall function as a risk marker for cardiovascular disease.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1999;17(5):S41-4.
1999: Carson P; Ziesche S; Johnson G; Cohn J N
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
Journal of cardiac failure 1999;5(3):178-87.
1999: Cohn J N; Tognoni G; Glazer R D; Spormann D; Hester A
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
Journal of cardiac failure 1999;5(2):155-60.
1999: McVeigh G E; Bratteli C W; Morgan D J; Alinder C M; Glasser S P; Finkelstein S M; Cohn J N
Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance.
Hypertension 1999;33(6):1392-8.
1999: Cohn J N
Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease.
Progress in cardiovascular diseases 1999;41(6):441-50.
1999: Baruch L; Anand I; Cohen I S; Ziesche S; Judd D; Cohn J N
Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Circulation 1999;99(20):2658-64.
1999: Tian B; Carlyle W C; Weigold W G; McDonald K M; Judd D L; Toher C A; Homans D C; Cohn J N
Localization of changes in beta-actin expression in remodeled canine myocardium.
Journal of molecular and cellular cardiology 1999;31(4):751-60.
1999: Cohn J N
Prevention of heart failure.
Cardiology 1999;92 Suppl 1():22-5; discussion 26-8.
1999: Cohn J N
Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.
Cardiology 1999;91 Suppl 1():19-22.
1998: Cohn J N; Goldstein S O; Greenberg B H; Lorell B H; Bourge R C; Jaski B E; Gottlieb S O; McGrew F; DeMets D L; White B G
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
The New England journal of medicine 1998;339(25):1810-6.
1998: McDonald K M; D'Aloia A; Parrish T; Mock J; Hauer K; Stillman A E; Cohn J N
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.
Journal of cardiac failure 1998;4(3):203-12.
1998: Cohn J N
Beta-blockers in heart failure.
European heart journal 1998;19 Suppl F():F52-5.
1998: Glasser S P; Arnett D K; McVeigh G E; Finkelstein S M; Bank A K; Morgan D J; Cohn J N
The importance of arterial compliance in cardiovascular drug therapy.
Journal of clinical pharmacology 1998;38(3):202-12.
1998: Cohn J N
Evaluating pathophysiologic processes rather than clinical end points in improving therapeutic practice.
Journal of cardiovascular pharmacology 1998;32 Suppl 3():S38-40.
1997: McDonald K M; Chu C; Francis G S; Carlyle W; Judd D L; Hauer K; Hartman M; Cohn J N
Effect of delayed intervention with ACE-inhibitor therapy on myocyte hypertrophy and growth of the cardiac interstitium in the rat model of myocardial infarction.
Journal of molecular and cellular cardiology 1997;29(12):3203-10.
1997: Cohn J N
Overview of the treatment of heart failure.
The American journal of cardiology 1997;80(11A):2L-6L.
1997: Glasser S P; Arnett D K; McVeigh G E; Finkelstein S M; Bank A J; Morgan D J; Cohn J N
Vascular compliance and cardiovascular disease: a risk factor or a marker?
American journal of hypertension 1997;10(10 Pt 1):1175-89.
1997: Cohn J N; Fowler M B; Bristow M R; Colucci W S; Gilbert E M; Kinhal V; Krueger S K; Lejemtel T; Narahara K A; Packer M; Young S T; Holcslaw T L; Lukas M A
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
Journal of cardiac failure 1997;3(3):173-9.
1997: Cohn J N; Ziesche S; Smith R; Anand I; Dunkman W B; Loeb H; Cintron G; Boden W; Baruch L; Rochin P; Loss L
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
Circulation 1997;96(3):856-63.
1997: McVeigh G E; Morgan D J; Finkelstein S M; Lemay L A; Cohn J N
Vascular abnormalities associated with long-term cigarette smoking identified by arterial waveform analysis.
The American journal of medicine 1997;102(3):227-31.
1997: Cohn J N
Current concepts in the treatment of congestive heart failure.
Cardiology 1997;88 Suppl 2():2-6.
1996: Cohn J N
Prognosis in congestive heart failure.
Journal of cardiac failure 1996;2(4 Suppl):S225-9.
1996: Colucci W S; Packer M; Bristow M R; Gilbert E M; Cohn J N; Fowler M B; Krueger S K; Hershberger R; Uretsky B F; Bowers J A; Sackner-Bernstein J D; Young S T; Holcslaw T L; Lukas M A
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
Circulation 1996;94(11):2800-6.
1996: Cohn J N
The management of chronic heart failure.
The New England journal of medicine 1996;335(7):490-8.
1996: Cohn J N
Left ventricular dysfunction and heart failure. Mechanistic and therapeutic distinctions.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1996;18(3-4):559-68.
1996: Carlyle W C; Toher C A; Vandervelde J R; McDonald K M; Homans D C; Cohn J N
Changes in beta-actin mRNA expression in remodeling canine myocardium.
Journal of molecular and cellular cardiology 1996;28(1):53-63.
1995: Cohn J N
Structural changes in cardiovascular disease.
The American journal of cardiology 1995;76(15):34E-37E.
1995: Cohn J N
A symposium: from hypertension to heart failure: endothelial dysfunction and structural changes in cardiovascular disease. Introduction.
The American journal of cardiology 1995;76(15):1E-2E.
1995: Cohn J N; Finkelstein S; McVeigh G; Morgan D; LeMay L; Robinson J; Mock J
Noninvasive pulse wave analysis for the early detection of vascular disease.
Hypertension 1995;26(3):503-8.
1995: Cohn J N
Critical review of heart failure: the role of left ventricular remodeling in the therapeutic response.
Clinical cardiology 1995;18(9 Suppl 4):IV4-12.
1995: McDonald K M; Mock J; D'Aloia A; Parrish T; Hauer K; Francis G; Stillman A; Cohn J N
Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis.
Circulation 1995;91(7):2043-8.
1995: Ziesche S; Rector T S; Cohn J N
Interobserver discordance in the classification of mechanisms of death in studies of heart failure.
Journal of cardiac failure 1995;1(2):127-32.
1995: Cohn J N
Plasma norepinephrine and mortality.
Clinical cardiology 1995;18(3 Suppl I):I9-12.
1995: Francis G S; McDonald K; Chu C; Cohn J N
Pathophysiologic aspects of end-stage heart failure.
The American journal of cardiology 1995;75(3):11A-16A.
1994: McDonald K M; Garr M; Carlyle P F; Francis G S; Hauer K; Hunter D W; Parish T; Stillman A; Cohn J N
Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog.
Circulation 1994;90(6):3034-46.
1994: McDonald K M; Rector T; Carlyle P F; Francis G S; Cohn J N
Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage.
Journal of the American College of Cardiology 1994;24(7):1762-8.
1994: Cohn J N
Physiological rationale for co-treatment with diuretics in heart failure.
British heart journal 1994;72(2 Suppl):S63-7.
1994: Cohn J N
Has the problem of heart failure been solved?
The American journal of cardiology 1994;73(10):40C-43C.
1994: McDonald K M; Yoshiyama M; Francis G S; Ugurbil K; Cohn J N; Zhang J
Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction.
Journal of the American College of Cardiology 1994;23(3):786-93.
1994: Connelly T P; Francis G S; Williams K J; Beltran A M; Cohn J N
Interaction of intravenous atrial natriuretic factor with furosemide in patients with heart failure.
American heart journal 1994;127(2):392-9.
1994: Cohn J N
Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
Drugs 1994;47 Suppl 4():47-57; discussion 57-8.
1993: Cohn J N
Efficacy of vasodilators in the treatment of heart failure.
Journal of the American College of Cardiology 1993;22(4 Suppl A):135A-138A.
1993: Cohn J N
Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure.
The American journal of cardiology 1993;72(8):21C-24C; discussion 24C-26C.
1993: Dunkman W B; Johnson G R; Carson P E; Bhat G; Farrell L; Cohn J N
Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI94-101.
1993: Rector T S; Johnson G; Dunkman W B; Daniels G; Farrell L; Henrick A; Smith B; Cohn J N
Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI71-7.
1993: Ziesche S; Cobb F R; Cohn J N; Johnson G; Tristani F
Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI56-64.
1993: Cohn J N; Johnson G R; Shabetai R; Loeb H; Tristani F; Rector T; Smith R; Fletcher R
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI5-16.
1993: Francis G S; Cohn J N; Johnson G; Rector T S; Goldman S; Simon A
Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI40-8.
1993: Goldman S; Johnson G; Cohn J N; Cintron G; Smith R; Francis G
Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI24-31.
1993: Cintron G; Johnson G; Francis G; Cobb F; Cohn J N
Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI17-23.
1993: Carson P E; Johnson G R; Dunkman W B; Fletcher R D; Farrell L; Cohn J N
The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI102-10.
1993: Cohn J N
The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
Circulation 1993;87(6 Suppl):VI1-4.
1993: Cohn J N
Post-MI remodeling.
Clinical cardiology 1993;16(5 Suppl 2):II21-4.
1993: Rector T S; Kubo S H; Cohn J N
Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo.
The American journal of cardiology 1993;71(12):1106-7.
1993: Francis G S; McDonald K M; Cohn J N
Neurohumoral activation in preclinical heart failure. Remodeling and the potential for intervention.
Circulation 1993;87(5 Suppl):IV90-6.
1993: McDonald K M; Francis G S; Matthews J; Hunter D; Cohn J N
Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog.
Journal of the American College of Cardiology 1993;21(2):514-22.
1993: McVeigh G E; Finkelstein S M; Cohn J N
Assessment of arterial compliance in hypertension.
Current opinion in nephrology and hypertension 1993;2(1):82-6.
1992: Cohn J N
Pharmacologic mechanisms of nitrates in myocardial ischemia.
The American journal of cardiology 1992;70(17):38G-42G.
1992: Rector T S; Cohn J N
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
American heart journal 1992;124(4):1017-25.
1992: Cohn J N
Mechanisms of action and efficacy of nitrates in heart failure.
The American journal of cardiology 1992;70(8):88B-92B.
1992: Cohn J N; Finkelstein S M
Abnormalities of vascular compliance in hypertension, aging and heart failure.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1992;10(6):S61-4.
1992: Finkelstein S M; Cohn J N
First- and third-order models for determining arterial compliance.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1992;10(6):S11-4.
1992: McDonald K M; Parrish T; Wennberg P; Stillman A E; Francis G S; Cohn J N; Hunter D
Rapid, accurate and simultaneous noninvasive assessment of right and left ventricular mass with nuclear magnetic resonance imaging using the snapshot gradient method.
Journal of the American College of Cardiology 1992;19(7):1601-7.
1992: McDonald K M; Francis G S; Carlyle P F; Hauer K; Matthews J; Hunter D W; Cohn J N
Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog.
Journal of the American College of Cardiology 1992;19(2):460-7.
1991: Cohn J N
Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
Herz 1991;16 Spec No 1():267-71.
1991: Cohn J N; Johnson G; Ziesche S; Cobb F; Francis G; Tristani F; Smith R; Dunkman W B; Loeb H; Wong M
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
The New England journal of medicine 1991;325(5):303-10.
1991: McVeigh G E; Burns D E; Finkelstein S M; McDonald K M; Mock J E; Feske W; Carlyle P F; Flack J; Grimm R; Cohn J N
Reduced vascular compliance as a marker for essential hypertension.
American journal of hypertension 1991;4(3 Pt 1):245-51.
1991: Cohn J N
Future directions in vasodilator therapy for heart failure.
American heart journal 1991;121(3 Pt 1):969-74.
1990: Kubo S H; Rector T S; Heifetz S M; Sato H; Cohn J N
Atrial natriuretic factor attenuates sympathetic reflexes during lower body negative pressure in normal men.
Journal of cardiovascular pharmacology 1990;16(6):881-9.
1990: Cohn J N
Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition.
The American journal of cardiology 1990;66(11):2D-6D.
1990: Carlyle P F; Cohn J N
Systemic and regional hemodynamic effects of alpha-adrenoceptor blockade in chronic left ventricular dysfunction in the conscious dog.
American heart journal 1990;120(3):619-24.
1990: Cohn J N
Nitrates are effective in the treatment of chronic congestive heart failure: the protagonist's view.
The American journal of cardiology 1990;66(4):444-6.
1990: Cohn J N
Abnormalities of peripheral sympathetic nervous system control in congestive heart failure.
Circulation 1990;82(2 Suppl):I59-67.
1990: Carson P; Carlyle P; Rector T S; Cohn J N
Cardiovascular and neurohormonal effects of atrial natriuretic peptide in conscious dogs with and without chronic left ventricular dysfunction.
Journal of cardiovascular pharmacology 1990;16(2):305-11.
1990: Cohn J N
Neuroendocrine activation after acute myocardial infarction.
The American journal of cardiology 1990;65(19):28I-31I.
1990: Cohn J N
Hepatocirculatory failure: diverse pathogeneses deserve diverse therapies.
Hepatology (Baltimore, Md.) 1990;11(3):510-1.
1990: McDonald K M; Carlyle P F; Matthews J; Hauer K; Elbers T; Hunter D; Cohn J N
Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition.
Transactions of the Association of American Physicians 1990;103():229-35.
1989: Kubo S H; Rector T S; Heifetz S M; Cohn J N
Alpha 2-receptor-mediated vasoconstriction in patients with congestive heart failure.
Circulation 1989;80(6):1660-7.
1989: Cohn J N
Sympathetic nervous system activity and the heart.
American journal of hypertension 1989;2(12 Pt 2):353S-356S.
1989: Cohn J N
Unloading the failing heart. Previous experience and future directions.
American journal of hypertension 1989;2(9):736-9.
1989: Cohn J N
Left ventricular function after myocardial infarction.
Journal of cardiovascular pharmacology 1989;14 Suppl 9():S55-8.
1989: Cohn J N
The sympathetic nervous system in heart failure.
Journal of cardiovascular pharmacology 1989;14 Suppl 5():S57-61.
1988: Cohn J N
Current therapy of the failing heart.
Circulation 1988;78(5 Pt 1):1099-107.
1988: Finkelstein S M; Collins V R; Cohn J N
Arterial vascular compliance response to vasodilators by Fourier and pulse contour analysis.
Hypertension 1988;12(4):380-7.
1988: Cohn J N
Is neurohormonal activation deleterious to the long-term outcome of patients with congestive heart failure? III. Antagonist's viewpoint.
Journal of the American College of Cardiology 1988;12(2):554-8.
1988: Cohn J N; Rector T S
Prognosis of congestive heart failure and predictors of mortality.
The American journal of cardiology 1988;62(2):25A-30A.
1987: Tristani F E; Hughes C V; Archibald D G; Sheldahl L M; Cohn J N; Fletcher R
Safety of graded symptom-limited exercise testing in patients with congestive heart failure.
Circulation 1987;76(6 Pt 2):VI54-8.
1987: Olivari M T; Levine T B; Ring W S; Simon A; Cohn J N
Normalization of sympathetic nervous system function after orthotopic cardiac transplant in man.
Circulation 1987;76(5 Pt 2):V62-4.
1987: Cohn J N
Role of nitrates in congestive heart failure.
The American journal of cardiology 1987;60(15):39H-43H.
1987: Cohn J N
Role of drugs for systemic hypertension and their effect on the heart.
The American journal of cardiology 1987;60(12):72G-74G.
1987: Cohn J N; Archibald D G; Francis G S; Ziesche S; Franciosa J A; Harston W E; Tristani F E; Dunkman W B; Jacobs W; Flohr K H
Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
Circulation 1987;75(5 Pt 2):IV49-54.
1987: Mock J; Finkelstein S M; Eaton J; Hatfield G; Cohn J N
Vascular compliance changes in hypertensive dogs during nitroprusside infusion as measured by pulse-contour-analysis.
Biomedical sciences instrumentation 1987;23():77-82.
1986: Cohn J N; Archibald D G; Ziesche S; Franciosa J A; Harston W E; Tristani F E; Dunkman W B; Jacobs W; Francis G S; Flohr K H
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
The New England journal of medicine 1986;314(24):1547-52.
1985: Rector T S; Carlyle P F; Cohn J N
Reduced atrial natriuretic factor after ligation of the left coronary artery in rats.
American heart journal 1985;110(6):1197-9.
1985: Finkelstein S M; Cohn J N; Collins V R; Carlyle P F; Shelley W J
Vascular hemodynamic impedance in congestive heart failure.
The American journal of cardiology 1985;55(4):423-7.
1983: Franciosa J A; Wilen M; Ziesche S; Cohn J N
Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy.
The American journal of cardiology 1983;51(5):831-6.
1982: Cohn J N; Franciosa J A; Francis G S; Archibald D; Tristani F; Fletcher R; Montero A; Cintron G; Clarke J; Hager D; Saunders R; Cobb F; Smith R; Loeb H; Settle H
Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study.
The New England journal of medicine 1982;306(19):1129-35.
1980: Zobel L R; Finkelstein S M; Carlyle P F; Cohn J N
Pressure pulse contour analysis in determining the effect of vasodilator drugs on vascular hemodynamic impedance characteristics in dogs.
American heart journal 1980;100(1):81-8.

Sign-in to see more